. Low LBNP tolerance in men is associated with attenuated activation of the renin-angiotensin system. Am J Physiol Regulatory Integrative Comp Physiol 279: R822-R829, 2000.-Plasma vasoactive hormone concentrations [epinephrine (p Epi ), norepinephrine (p NE ), ANG II (p ANG II ), vasopressin (p VP ), endothelin-1 (p ET-1 )] and plasma renin activity (p RA ) were measured periodically and compared during lower body negative pressure (LBNP) to test the hypothesis that responsiveness of the renin-angiotensin system, the latter being one of the most powerful vasoconstrictors in the body, is of major importance for LBNP tolerance. Healthy men on a controlled diet (2,822 cal/day, 2 mmol ⅐ kg Ϫ1 ⅐ day Ϫ1 Na ϩ ) were exposed to 30 min of LBNP from Ϫ15 to Ϫ50 mmHg. LBNP was uneventful for seven men [25 Ϯ 2 yr, high-tolerance (HiTol) group], but eight men (26 Ϯ 3 yr) reached presyncope after 11 Ϯ 1 min [P Ͻ 0.001, low-tolerance (LoTol) group]. Mean arterial pressure (MAP) did not change measurably, but central venous pressure and left atrial diameter decreased similarly in both groups (5-6 mmHg, by Ϸ30%, P Ͻ 0.05). Control (0 mmHg LBNP) hormone concentrations were similar between groups, however, p RA differed between them (LoTol 0.6 Ϯ 0.1, HiTol 1.2 Ϯ 0.1 ng ANG I ⅐ ml Ϫ1 ⅐ h
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, P Ͻ 0.05). LBNP increased (P Ͻ 0.05) p RA and p ANG II , respectively, more in the HiTol group (9.9 Ϯ 2.2 ng ANG I ⅐ ml Ϫ1 ⅐ h Ϫ1 and 58 Ϯ 12 pg/ml) than in LoTol subjects (4.3 Ϯ 0.9 ng ANG I ⅐ ml Ϫ1 ⅐ h Ϫ1 and 28 Ϯ 6 pg/ml). In contrast, the increase in p VP was higher (P Ͻ 0.05) in the LoTol than in the HiTol group. The increases (P Ͻ 0.05) for p NE were nonsignificant between groups, and p ET-1 remained unchanged. Thus there may be a causal relationship between attenuated activation of p RA and p ANG II and presyncope, with p VP being a possible cofactor. Measurement of resting p RA may be of predictive value for those with lower hypotensive tolerance. hypotensive tolerance; vasopressin; central venous pressure; catecholamines THE MECHANISM FOR REDUCTION of cerebral blood pressure resulting in syncope (fainting) in humans is not clear.
Multiple interactive factors such as hypovolemia (11) , altered baroreceptor function (17, 23) , attenuated sympathetic vascular resistance (16) , and the action of vasoactive hormones (7, 9, 11, 12, 17, 18, 21) are probably involved in this mechanism. Although the effect of various interactive catecholamine and cardiovascular responses on hypotension have been investigated intensively (24) , relatively few investigators have studied the hypotensive association of the noncatecholamine vasoactive hormonal responses, e.g., the renin-angiotensin-aldosterone (RAA) axis in the kidney and the vasopressin system in the brain (7-9, 11, 12, 18, 21) . ANG II is one of the most powerful vasoconstrictors in the body, and its attenuated action might inhibit vasoconstriction during extreme hypotensive stress, such as lower body negative pressure (LBNP), where the usual muscular pressure on the caudal veins is absent. Oparil et al. (19) reported that in the 5 of 20 normotensive men and women who exhibited vasovagal syncope after 80°head-up tilt, the increase in plasma renin activity (p RA ) was smaller in magnitude and duration than in the other subjects. On the other hand, Harrison et al. (9) found that 7 of 13 subjects who exhibited tilt intolerance had consistently lower systolic and pulse pressures (PP) and significantly higher p RA .
However, these vasoactive hormones do not act independently but appear to have significant interaction. On the basis of serial blood samples taken during progressive hypotension at 55 mmHg LBNP, it has been reported that the vasoactive hormone response starts with the catecholamines, progresses to the RAA system, and ends with the vasopressin axis (21), a sequence that also occurred during 70°head-up tilting in both men and women (6) .
Thus the purpose for this study was to determine whether the neuroendocrine activation would differ in higher and lower tolerance subjects and to test the hypothesis that the RAA system is the more important for differentiating men with lower hypotensive tolerances.
METHODS
Fifteen healthy, nonsmoking, male volunteers were selected as test subjects after passing a medical examination and giving informed consent. After LBNP testing was completed, they were allocated into two groups: those who tolerated 20 The men slept in the laboratory the night before testing and consumed no food or fluid after 2100 from the previous day to experiment termination. They were awakened at 0745, urinated to close their 24-h sample, were weighed, and then entered the LBNP chamber supine onto a narrow padded saddle without foot support to start the experiment at 0800 when the central venous pressure (CVP) catheter was inserted and electrocardiogram electrodes applied. The protocol for the 165-min ambient control period was 60 min rest supine with the last 15 min for plasma volume (PV) measurement, then 60 min sitting (last 15 min for PV) and a final 45 min supine to determine that PV increases from sitting to supine (Fig. 1) . Changing body position required ϳ2 min. This 165-min ambient period was followed by the LBNP period (supine): 10 min at ambient pressure, 10 min at Ϫ15 mmHg, 20 min at Ϫ50 mmHg or until onset of presyncopal signs or symptoms (point of intolerance), and finally 10 min of recovery at ambient pressure. Presyncopal signs and symptoms included stomach awareness, nausea, sweating, narrowing of vision, or dizziness or, if those did not occur, a rapid drop in mean arterial pressure and/or bradycardia. Time (min) on the figures indicated the start of the 3-min interval when blood sampling commenced. The final Ϫ50-mmHg blood sample was taken as close as possible to the onset of presyncopal signs or symptoms. Mean (ϮSE) ambient dry-bulb temperature was 25.6 Ϯ 1.3°C, and relative humidity was 38 Ϯ 4%.
The integrated heart rate was displayed on a Diascope monitor (model DS 521, Simonsen and Weel, Copenhagen, Denmark) and was counted manually from a three-lead electrocardiogram. Arm cuff blood pressures were displayed on a Protocol Systems monitor (model Propaq 102, Beaverton, OR), but PP and MAP {1/3 [systolic blood pressure (SBP) Ϫ diastolic blood pressure (DPB)] ϩ DBP} pressures were calculated manually from a Finapres Monitor trace (model Ohmeda 2300, Englewood, CO) with the sensor positioned on the mid-and distal phalanx of the right middle or third finger. A CVP catheter assembly (16 gauge, 1.7 mm ID with a 14-gauge injection catheter, model Cavafix Certo, B. Braun, Melsungen, Germany) was inserted via a right antecubital vein. Another catheter (18 gauge, model Venflon 2, BOC Ohmeda AB, Helsingborg, Sweden) was inserted into a left forearm vein for injection of Evans blue dye (Pharmacie Hopital E. Herriot, Lyon, France). Heart rate, systemic (Propac) blood pressures, and CVP data were displayed and recorded continuously on a Gould (model V1000, Ballainvilliers, France) oscilloscope and model ES1000 strip-chart recorder, respectively. Heart images were displayed on an echocardiograph (model SSD-500, Aloka, Tokyo, Japan), recorded on a Sony (model SVO 9500 MPD) videocassette recorder, and printed for analysis later.
The CVP catheter was advanced to an intrathoracic vein near the superior vena cava, where its position was verified by the characteristic waveform and responses to respiratory maneuvers. The subject's arms were supported horizontally at heart level, and the electronically integrated pressure trace was calibrated frequently. Pressure calibration levels were determined manually with a water column.
Mean end-expiratory left atrial diameter (LAD) measurements, obtained at 3-min intervals during the LBNP period from 3 M-mode prints, were taken by echocardiography from the parasternal long-axis view. The LAD were measured blind (3).
The two PV determinations required 10 3-ml blood samples (30 ml) and four 2-ml samples (8 ml) for hematocrit (Hct) plus a maximum of 14 20-ml samples (280 ml) for p RA and for plasma vasoactive hormone concentrations [epinephrine (p Epi ), norepinephrine (p NE ), ANG II (p ANG II ), and vasopressin (p VP )] analyses (at 3-min intervals) and five 5-ml samples for plasma vasoactive hormone concentration of endothelin-1 (p ET-1 , 25 ml at 10-min intervals) during the LBNP period http://ajpregu.physiology.org/ depending on the onset of presyncopal signs or symptoms (when the experiment was terminated; Fig. 1 ). Maximal blood volume withdrawn was 343 ml/experiment; of that, the discarded presample dead-space volume was 42 ml, whereas that from the Evans blue test was reinjected.
The blood was transferred to chilled polyethylene tubes containing appropriate anticoagulants and buffers. For p Epi and p NE , the tubes contained 20 l/ml of blood with 0.195 M reduced glutathione and 0.250 M EGTA adjusted with NaOH to pH range 6-7. For p VP , p ANG II , and p ET-1 , the tubes contained 25 l EDTA and 2,700 KIU of Trasylol R, i.e., aprotinin (Novo Nordisk, Bagsvaerd, Denmark). The tubes were oscillated gently, iced, centrifuged at 1,500 g for 10 min at 4°C, and stored at Ϫ18°C for batch analysis.
Albumin space was determined after 45 min rest supine and sitting with intravenous injection of Evans blue dye via the forearm catheter in eight subjects (5 HiTol and 3 LoTol group). The central venous catheter allowed for a 3-ml preinjection blood sample taken at Ϫ1 min and postinjection samples at 5, 7, 10, and 15 min into tubes containing 12.5 IU heparin/ml. Plasma dye concentration was measured on each sample at 620 and 740 nm (Hitachi, model U-1000 spectrophotometer) before each injection of dye and also in the postinjection samples, so extraction was unnecessary. Quadruplicate microhematocrit tubes were centrifuged at 12,000 g for 5 min in a Struers Kebo model 3K10 centrifuge (Sigma Laborzentrifugen, Osterode am Harz, Germany) and corrected with a plasma centrifugation trapping factor of 0.96 and body-venous F-cell factor of 0.91. Plasma and blood volumes were measured and calculated (4) . p VP was measured by radioimmunoassay (2) with plasma extracted by Sep-Pak C 18 columns (Waters, Milford, MA) preconditioned sequentially with 5 ml each of 4% acetic acid in 96% ethanol, 100% methanol, water, and 4% acetic acid. Two milliliters of plasma acidified with 6 ml of 4% acetic acid were run through the columns that were then washed with 5 ml of water. The peptide was eluted with 3 ml of 4% acetic acid in 60% ethanol into Minisorp R tubes (Nunc, Roskilde, Denmark) containing 10 l (0.1%) of Triton X-100 (octyl phenoxy polyethoxyethanol, Sigma Aldrich Vallensbaek, Strand, Denmark). The air-dried eluate was adjusted to pH 7.4 with 750 l of assay buffer, (0.1 M phosphate buffer with [0.01 M K 2 EDTA, 0.01 M NaN 3 , and 1.0 mg/ml of serum albumin) (Behringwerke, Marburg, Germany). Then 300 l each of test sample and standard were incubated for 24 h with 300 l of antibody (AB3096).
125 I vasopressin (New England Nuclear, Life Sciences Products, Boston, MA), containing 2,200 Ci/mmol (100 l, 8,000 disintegrations/min), was added, and incubation was continued for an additional 24 h. Bound was separated from free antigen with 1,050 l of a charcoal-plasma suspension (10.8 g charcoal, and 60 l of plasma in 300 l of buffer). After centrifugation, the supernate radioactivity was measured. The detection limit of the assay was 0.1-0.2 pg/ml. Mean recovery was 73% and the intra-assay coefficiant of variation (CV) was Ϯ 6.5% at 2.0 pg/ml and 9.0% at 2.4 pg/ml. p ANG II was measured by radioimmunoassay (13) with plasma extracted by Sep-Pak C 18 columns activated with 5 ml methanol followed by 5 ml water. Then, 2.2 ml of plasma containing a tracer amount of ANG II (for recovery determination) were added to the columns, which were washed with 5 ml water and 5 ml 20% methanol in water, and the ANG II was then eluated with 2 ml of methanol. The eluate, dried with N 2 at 37°C, was dissolved in 1.5 ml of buffer (0.1 M Tris ⅐ HCl with 0.2% BSA and 10 mM Na 2 EDTA).
125 I-labeled ANG II and diluted antiserum were added to aliquots of the extracted plasma and incubated at 4°C for 18 h. Separation of bound from free antibody-radioiodinated ANG II was by charcoal absorption. The detection limit of the assay (1.4 pg) was estimated as the quantity of ANG II that displaced 10% of the binding of the radioiodinated label alone. Mean recovery of ANG II was 69 Ϯ 7%, and intra-assay CV was Ϯ 8%. Results were not corrected for incomplete recovery.
p ET-1 was measured by radioimmunoassay (1, 22) with plasma extracted by Sep-Pak C 18 columns (Waters Milford, MA) preconditioned sequentially with 5 ml each of 4% acetic acid in 96% ethanol, 100% methanol, water, and 4% acetic acid. Two milliliters of plasma, acidified with 6 ml of 4% acetic acid, were run through the columns that were then washed with 5 ml of water. The peptide was eluted with 3 ml of 4% acetic acid in 96% ethanol into minisorp R tubes (Nunc, Roskilde, Denmark) containing 10 l (0.1%) of Triton X-100. The air-dried eluate was adjusted to pH 7.4 with 550 l of assay buffer (0.01 M phosphate buffer with 0.01 M K 2 EDTA and 0.001 M NaN 3 and 1.0 mg/ml of human serum albumin) (Behringwerke, Marburg, Germany). Then 200 l each of test sample and standard were incubated for 24 h with 100 l of antibody RAS6901 (Peninsula Laboratories Europe, St. Helens, UK). Then, 50 l (6,000 disintegrations/min) of I 125 -labeled ET-1 (New England Nuclear Life Sciences Products, Boston, MA) were added, and incubation was continued for an additional 24 h. Bound was separated from free antigen with 1,050 l of a charcoal-plasma suspension (10.8 g charcoal and 60 l of plasma in 300 l of buffer). After centrifugation, the supernatant radioactivity was measured. The detection limit of the assay was Ͻ0.6 pg/tube, and the extraction recovery of unlabeled ET-1 was 100% from plasma. Interassay CV was 10% at an ET-1 concentration of 6 pg/ml. p E and p NE were measured with a radioenzymatic assay (14) . Plasma was precipitated with an equal volume of perchloric acid, and 100 l of the supernatant were incubated with the enzyme carboxy-O-methyl-transferase. After incubation, unlabeled metanephrine and normetanephrine were added to the supernatant, and samples were extracted with an isoamylalcohol-toluene mixture. These extracted samples were acidified with HCl, and 120 l were injected into an HPLC (Waters model 600) where a 120 ϫ 3 mm Nucleosil C 18 reverse-phase column separated the metanephrine and normetanephrine. The mobile phase consisted of dilute phosphoric acid (30 mM, pH 1.8) with 2% methanol added before use. The cold metanephrines were measured at 276 nm (ultraviolet) to ensure that the labeled samples were collected at appropriate elution times (for example, at 2.6 min for normetanephrine and 4.0 min for metanephrine). The eluate was collected in 1.0-min fractions centered on those intervals. There was no crossover between the two peaks. Then, 3 H-labeled metanephrine and normetanephrine were oxidized to vanillin and counted with liquid scintillation spectrometry. Intra-assay CV for normal, basal levels of epinephrine and norepinephrine were 8% and 6%, respectively; corresponding interassay CV were 11% and 7%, respectively. Intra-assay sensitivity (3 ϫ standard deviation of the blank) was 0.3 pg/assay for epinephrine and 0.5 pg/assay for norepinephrine; corresponding inter-assay sensitivity was 0.5 pg/assay for both variables.
Statistical analyses. Anthropometric, environmental, dietary control, and LBNP tolerance data were analyzed with the t-statistic for independent groups (HP-65, Stat-Pac 1 no. 1-30A, Hewlett-Packard, Cupertino, CA). The difference between PV in the supine and sitting positions was determined with the paired t-test (HP-65, no. 1-29A). Remaining data from the two groups over time were analyzed first with one-way ANOVA (SPSS 7.5 for Windows, SPSS, 1996, Chicago, IL). Because of the inconsistent experiment termina-tion times in the LoTol group, subsequent differences between groups were also determined with the Kruskal-Wallis H-test (15), a nonparametric analog of one-way ANOVA. All presyncopal data through 12 min were included in the analysis; data for the one subject at 15 min were omitted. Significant data indicated in the figures were significant by both ANOVA and the Kruskal-Wallis tests. An intercorrelation matrix (Pearson-product moment, SPSS 7.5 for Windows) was calculated with cardiovascular and hormonal variables. The null hypothesis was rejected when P Ͻ 0.05, and nonsignificant differences were denoted NS.
RESULTS
LBNP tolerance. All HiTol subjects completed 20 min of Ϫ50-mmHg pressure with no adverse signs, symptoms, or discontinuities in their cardiovascular or hormonal data (Figs. 2 and 3) . The LoTol group's intolerance ranged from 6 to 15 min (mean ϭ 11 Ϯ 1 min, t ϭ 9.01, P Ͻ 0.001). Numbers of subjects at each intolerance time at Ϫ50 mmHg were as follows: 6 min for all 8 subjects, 9 min for 7 subjects, 12 min for 6 subjects, and 15 min for 1 subject. The mean values at 18 min in the figures are their final intolerance levels irrespective of time.
Plasma and blood volumes. PV data from the two groups (n ϭ 8) were not significantly different, so they were combined for analysis. Mean (ϮSE) PV in the sitting position (3,557 Ϯ 126 ml, 42 ml/kg) was increased in the supine position to 3,911 Ϯ 153 ml (10.0%, t ϭ 5.01, P Ͻ 0.001); corresponding calculated blood volumes increased from 5,975 Ϯ 229 ml (71 ml/kg) sitting to 6,403 Ϯ 259 ml (7.2%, t ϭ 4.18, P Ͻ 0.002) supine.
Cardiovascular responses. After 60 min supine, there were no significant differences in heart rate (range 52 Ϯ 3 to 60 Ϯ 4 beats/min) or in SBP (range 116 Ϯ 3 to 127 Ϯ 3 mmHg), DBP (range 72 Ϯ 2 to 77 Ϯ 2 mmHg), or PP (range 40 Ϯ 3 to 50 Ϯ 2 mmHg) over time or between groups during the supine 10-min control period and the ensuing 10 min of 15 mmHg LBNP (Table 1, Fig. 2 ). Onset of Ϫ50 mmHg by minute 3 resulted in increases (P Ͻ 0.05) in heart rate in both groups of 76 Ϯ 5 to 97 Ϯ 6 beats/min, no significant changes in SBP (121 to 116 mmHg) or DBP (76 to 79 mmHg), but PP decreased (P Ͻ 0.05) in both groups. From 9 to 12 min at Ϫ50 mmHg, there were no significant changes in heart rate or in SBP, DBP, or PP in either group. Essentially all SBP at Ϫ50 mmHg were decreased from their respective mean control levels, whereas DBPs were not (Table 1) .
MAP was not different between groups or over time during the control, LBNP, or recovery periods, but it tended to decrease (NS) in the LoTol group after 6 min at Ϫ50 mmHg (Fig. 2) . CVP was sensitive to progressive negative pressure, but there was no significant difference in CVP between groups during the entire experiment (Fig. 2) . CVP, unchanged (range 5.4-6.9 mmHg) during the control period, decreased significantly to 3.3-3.9 mmHg at Ϫ15 mmHg and further to 0.4-1.2 mmHg at Ϫ50 mmHg and had not increased to control levels by 5 min of recovery. Like CVP, the LAD was also sensitive to the progressive negative pressure (Fig. 2) , but the LoTol group's LAD were significantly greater than those for the HiTol group in the control, Ϫ15 mmHg, and recovery periods, but not during Ϫ50 mmHg. From the 9 min control level to 12 min at Ϫ50 mmHg, the LoTol group's LAD decreased from 37 to 25 mm (by 32%, P Ͻ 0.05); that in the HiTol group de- creased similarly from 30 to 21 mm (by 30%, P Ͻ 0.05), and both groups' LAD had recovered by 5 min. Plasma enzyme-hormonal responses. There were no statistically significant differences in plasma endothelin-1, a potent vasoconstrictor, between groups or over time during control through recovery: mean (ϮSE) values ranged from 3.2 Ϯ 0.4 to 4.1 Ϯ 0.3 pg/ml.
With the exception of similar control levels of p ANG II in both groups and its significant increase in the HiTol group during Ϫ15 mmHg, the responses of p RA and p ANG II were remarkably similar during Ϫ50 mmHg and recovery (Fig. 3) . The HiTol group's increases in p RA and p ANG II from control 9 min to Ϫ50 mmHg at 18 min (intolerance level) were ϳ8.0-and 7.7-fold, respectively, whereas those for LoTol were ϳ6.9-and 6.1-fold, respectively. Mean LoTol group tolerance (11 Ϯ 1 min) was reached at lower (P Ͻ 0.05) levels of p RA and p ANG II in the control and all subsequent periods. Higher tolerance individuals could be characterized by their higher (P Ͻ 0.05) resting levels of p RA . p VP was not significantly different between groups or over time in the control periods (range 0.4 Ϯ 0.1 to 0.7 Ϯ 0.3 pg/ml) or between groups during Ϫ15 mmHg (Fig. 2) . But the important differences between groups and over time occurred during Ϫ50 mmHg, where p VP increased more slowly but significantly in the HiTol group from 1.0 Ϯ 0.3 (at 9 min Ϫ15 mmHg) to reach 13.0 Ϯ 4.8 pg/ml [change (⌬) ϭ 12.0 pg/ml, P Ͻ 0.05] at 18 min, but it increased more quickly and significantly in the LoTol group from 0.9 Ϯ 0.2 to 54.7 Ϯ 18.3 pg/ml (⌬ ϭ 53.8 pg/ml, P Ͻ 0.05) at 18 min (mean intolerance). Vasopressin in the LoTol group at 12 min and Ϫ50 mmHg was probably higher than that in the HiTol group because of impending onset of presyncopal signs and symptoms. One LoTol group subject's p VP even reached 168.8 pg/ml at intolerance at 9 min and Ϫ50 mmHg. Thus compared with HiTol, accentuated p VP responses were found in the LoTol group in contrast to the attenuated responses of p RA and p ANG II .
p Epi was not significantly different between groups in the control, Ϫ15 and Ϫ50 mmHg, or recovery periods (Table 2 ). However, from control, it was significantly increased over time only at Ϫ50 mmHg in HiTol and at Ϫ15 and Ϫ50 mmHg in the LoTol group. On the other hand, the p NE concentration was more sensitive, whereas the mean values of the two groups were similiar in all periods, it increased significantly above control levels in both groups during Ϫ15 and Ϫ50 mmHg and did not recover until 10 min in the LoTol group (Fig. 3) . The p NE response pattern during Ϫ50 mmHg and recovery was similar to that of p VP ; although the p NE maximum response in the LoTol group occurred at 9 min and Ϫ50 mmHg, its maximal p VP response occurred at intolerance.
Because of the different scales for p RA , p ANG II , p VP , and p NE on the y-axis in Fig. 3 , it is difficult to determine possible onset sequences for a presyncopal enzyme-hormonal cascade, especially p ANG II and p NE at Ϫ15 mmHg, where there was significantly increased activity even when heart rate and various blood pressures were unchanged. When these combined hormonal responses from all subjects at 3, 6, and 9 min during Ϫ15 mmHg were expressed as respective percent changes in those intervals, there does not seem to be a general sequence of onset beginning with catecholamines and progressing to the RAA system and on , and heart rate (E) in the supine control and LBNP and recovery periods for the higher and lower tolerance groups. Numbers of subjects at each intolerance time at Ϫ50 mmHg were 6 min for all 8 subjects, 9 min for 7 subjects, 12 min for 6 subjects, and 15 min for 1 subject. Mean values at 18 min are final intolerance levels irrespective of time (dashed lines between 12 and 18 min). * P Ͻ 0.05 from the mean of the control values; ⌬ P Ͻ 0.05 between groups.
to p VP (18) . In fact, the p VP concentrations had the greater ranges and variability (ϮSD) of percent changes when compared with the other hormonal responses. When these data were ranked according to the upper end of their respective ranges (ϮSD), we observed a different order beginning with p VP 
DISCUSSION
Our protocol was designed to prolong the presyncopal period to better delineate vasoactive enzyme-hormonal activation by using an initial negative pressure of only 15 mmHg for 10 min and progressing to 50 mmHg for 20 min or until onset of presyncopal responses. This protocol was sufficient to allocate otherwise unresponsive men with "normal" tolerance into approximately equal higher and lower tolerance groups where there appears to be a wide range of normal LBNP tolerance from 16 min to more than 30 min. None of the subjects was aware of any abnormal syncopal responses in their daily lives.
It is clear that significant hormonal activation occurred in both groups at Ϫ15 mmHg when heart rate, PP, and MAP were unresponsive. Our data indicated the onset sequence was p VP 3p Epi 3p NE 3(p RA 3p ANG II) in the LoTol group and essentially the same in the HiTol group [p VP 3p NE 3p Epi (3 p RA 3p ANG II )], with the RAA system at the terminal end in both. The activation patterns of p RA and p ANG II were also similar in both tolerance groups at Ϫ50 mmHg (with due regard for the large difference in their y-axis scales in Fig. 3 ), i.e., they increased progressively during both lower and especially the higher levels of LBNP.
This RAA system response was probably not due to large variations in plasma cations, because the subjects were consuming the same sodium intake per kilogram of body weight coupled with similar urinary Na ϩ excretions before the experiment. Also, plasma cation and osmotic concentrations remain within normal control limits during the hypotensive hypovolemia that occurs during 70°head-up tilt (6) . Controlled sodium intake is important because it controls the extracellular fluid volume and renal sodium excretion (including distal tubular delivery) and because of its close interaction with control of blood pressure; e.g., exaggerated symptoms of hypotension are attenuated in Fig. 3 . Mean (ϮSE) plasma renin activity (A) and ANG II (B), vasopressin (C), and norepinephrine (D) concentrations in the supine control, LBNP, and recovery periods for the higher and lower tolerance groups. Numbers of subjects at each intolerance time at Ϫ50 mmHg were 6 min for all 8 subjects, 9 min for 7 subjects, 12 min for 6 subjects, and 15 min for 1 subject. Mean values at 18 min are final intolerance levels irrespective of time (dashed lines between 12 and 18 min). * P Ͻ 0.05 from the mean of the control values; ⌬ P Ͻ 0.05 between groups.
orthostatically intolerant patients on a high-sodium diet (20) .
p RA in the LoTol group was significantly lower than that in the HiTol group in the control period and throughout LBNP. Jacob et al. (11) suggested that reduced p RA , possibly from defective sympathetic activation of the kidney, could have facilitated fainting in chronically orthostatically intolerant patients via hypovolemia. They found a significant correlation (r ϭ ϩ0.84) between p RA and blood volume. It is well known that total body dehydration and hypovolemia reduce tilt tolerance (8) and accentuate p VP , p RA , and plasma aldosterone responses during tilt (7) . But resting control PVs from five high-and three low-tolerance men in the present study were not significantly different, and their plasma and blood volumes increased similarly when they moved from sitting to the supine position. However, the differences in LAD between the two groups suggest a change in volume in the central venous system. The similar decrease in CVP in both groups and different LADs imply low compliance in the low-pressure system. Even though the LoTol group had the usual increased catecholamine activity and p VP release during Ϫ50 mmHg, the discrepancy between increases in p ANG II and p VP in the two groups during LBNP is clear: when compared with HiTol group responses, the increase in p ANG II in the LoTol group was attenuated, whereas the increases in p NE and p VP were accentuated, suggesting no defect in the sympathetic nervous response. As a result, the LoTol group was unable to maintain MAP, leading to impending syncope.
The significant activation of norepinephrine in both groups during Ϫ15 mmHg LBNP was probably a result of the decreased CVP. This activation also reflects an increase in renal sympathetic nervous activity (RSNA), which released renin significantly in both groups at the end of Ϫ15 mmHg LBNP, but increased ANG II significantly only in the HiTol group at that point. Thus from the similar decrease in CVP, greater intolerance may be associated with the ability to increase RSNA and hence renin angiotensin in the kidney. Hence, differential intolerance may be determined by ability to increase RSNA.
Although p VP was activated somewhat during Ϫ15 mmHg LBNP, its massive release, which occured only during impending syncope at the end of the presyncopal cascade, is well documented (5, 9, 10). The vasopressin system has tremendous reserve capacity in that p VP concentrations in excess of 500 pg/ml (normal 1.5 pg/ml) have been measured at syncope (J. E. Greenleaf, personal observation). So it seems more likely that the large vasopressin release is a consequence and not a causal factor of impending syncope and nausea. Jardine et al. (12) also observed significant increases in p VP and the plasma hormone concentration of ACTH after 5 min of 60°head-up tilt in patients with a history suggestive of vasovagal reactions. It is unclear whether this large p VP response was induced by a sinoaortic baroreceptor response or vice versa. The similar significant rise in p NE in both groups might be an early stimulus that signals the possible impending vasopressor reaction. Thus increased sympathetic activity rather than the attenuated response to secrete more ANG II may have been a major initiating stimulus that resulted in the hypotensive intolerance. If the LoTol group was more predisposed to the vasopressor syncope by the increased sympathetic activity that resulted in a strong vagal stimulus, this stimulus could have inhibited RAA system activity. This explanation implies that the mechanism of the intolerance was a graded response in subjects of varying intolerance thresholds and should function similarly in all subjects at their varying presyncopal points. The question arises if the depressed p RA and/or p ANG II in the LoTol group was increased to equal that in the HiTol group, would the LoTol group's tolerance be increased significantly? If so, it would confirm the pivotal role of the RAA system in this hypotensive mechanism.
Our results confirm those of Mark et al. (17) who first reported that Ϫ40 mmHg LBNP decreased CVP and arterial PP which attenuated, respectively, both lowand high-pressure baroreceptor inhibition, i.e., reacti- ) only when both low-and high-pressure inhibition occurred and not with low pressure (Ϫ10-to Ϫ20 mmHg LBNP) inhibition alone. This pressure was comparable with the Ϫ15 mmHg LBNP used in the present study, in which p RA was also unchanged in both groups, whereas p ANG II was increased significantly in the HiTol group but was unchanged (inhibited?) in the LoTol group due to presumably reactivated low-pressure baroreceptors from the LBNP.
Norsk et al. (18) indicated that p VP during LBNP responds more to narrowing of the PP than to reduction of CVP. Results from the present study support this conclusion from the significant correlation between PP and p VP (r ϭ Ϫ0.52, P Ͻ 0.01) in the HiTol group, but not in the LoTol group (r ϭ Ϫ0.12, NS). We found similar results in the RAA system only in our HiTol group between PP vs. p RA and PP vs. p ANG II : the r were Ϫ0.55 and Ϫ0.56 (both P Ͻ 0.01), respectively. However, the respective r in our LoTol group were Ϫ0.36 and Ϫ0.24 (both NS). These findings strengthen the high-pressure hypothesis regarding the hormonal release action on PP, but it may not apply to lowertolerance subjects.
It is concluded that the response of the renin-angiotensin system appears to be linked inversely to the occurrence of presyncopal symptoms, and measurements of resting p RA may have predictive value for those with lower hypotensive tolerance.
Perspectives
If sufficiently confirmed, one major practical application of these findings concerning attenuation of the increase in p RA and p ANG II during hypotensive stress might be to provide a method for prognosticating lower orthostatic tolerance in normal, healthy people. An increase of hypotensive tolerance by infusing ANG II during LBNP would help to confirm this hypothesis.
